Progression-free survival increased with zanubrutinib in leukemia

Progression-free survival is significantly longer with zanubrutinib than ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to a study published ...


Researchers to test blood cancer drug in COVID-19 patients

Scientists at Dana-Farber Cancer Institute have launched a clinical test of a blood cancer drug in patients infected with the COVID-19 virus. The test follows several case reports in which the drug, ibrutinib, appeared to ...

page 1 from 2